Ultrahypofractionation utilizing SBRT is a high level method conveying enormous radiation portions in ≤5 therapies with cost and patient comfort points of interest. As treatment volumes are more modest and prohibit pelvic lymph hubs, it is transcendently used for low/middle of the road hazard PCa [1, 2]. In 2020, the NCCN added SBRT to ordinary/moderate radiation regimens to the rundown of alternatives for HR PCa however particularly when extended radiation courses present clinical/social difficulty [3]. This change happened after the randomized HYPO-RT-PC preliminary [4] indicated non-inadequacy of ultrahypofractionation contrasted with ordinary fractionation (~40 medicines) for tumor control and harmfulness in transitional and HR PCa following 5-year development. The change likewise continued an instructive meta-examination of 39 planned investigations which indicated good 5-and 7-year biochemical control and low poisonousness.
Reference link- https://www.nature.com/articles/s41391-020-00300-5
